This year, the impressive ESMO 2024 congress will take place in Barcelona, where we will be on site with the following presentations.
While the difference in overall survival has not yet reached statistical significance, pertuzumab remains an important therapeutic option due to the improved invasive disease-free survival in this patient group.
Successful inclusion of the first patient in our MOMENTUM study by the St. Vincenz Hospital trial center team in Limburg.
With 18 randomised patients, we have already reached 50% of our target in just under 6 months!
Keeping the ASCO24 slogan „Come from the science, stay for the connection, and leave with an inspiration that will drive you forward”, GBG is taking part in the following presentations this year…
Our leading experts continuously support physicians in their clinical decision-making with updated Clinical Practice Guidelines and Consensus Statements from European Society of Medical Oncology (ESMO).
